Compare INM & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INM | GCTK |
|---|---|---|
| Founded | 1981 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.4M |
| IPO Year | N/A | N/A |
| Metric | INM | GCTK |
|---|---|---|
| Price | $1.11 | $3.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 109.5K | 30.2K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,798,116.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $3.21 |
| 52 Week High | $8.27 | $169.20 |
| Indicator | INM | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 41.70 |
| Support Level | $1.03 | $3.52 |
| Resistance Level | $1.40 | $4.24 |
| Average True Range (ATR) | 0.09 | 0.41 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 24.32 | 72.82 |
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.